Suramin treatment in hormone- and chemotherapy-refractory prostate cancer

Urology

Volumn 53, Issue 3, 1999, Pages 535-541

  Garcia Schürmann, J Miguel ^a,b   Schulze, Harald ^a   Haupt, Gerald ^a   Pastor, Jobst ^a   Senge, Theodor ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETINDENE; HYDROCORTISONE; SURAMIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; EYE TOXICITY; HUMAN; INFECTION; KERATOPATHY; LEUKOPENIA; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; POLYNEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RASH; TREATMENT OUTCOME;

EID: 0033105316     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00544-5     Document Type: Article

References (26)

1. Levine A., Gill P., Cohen J., et al. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Intern Med. 105:1986;32-37.
2. Betsholtz C., Johnsson A., Heldin C., et al. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA. 83:1986;6440-6444.
3. Arlt W., Reincke M., Siekmann L., et al. Suramin in adrenocortical cancer limited efficacy and serious toxicity . Clin Endocrinol. 41:1994;299-307.
4. Myers C., Cooper M., Stein C., et al. Suramin a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer . J Clin Oncol. 10:1992;881-889.
5. Eisenberger M.A., Reyno L.M., Jodrell D.I., et al. Suramin, an active drug for prostate cancer interim observations in a phase I trial . J Natl Cancer Inst. 85:1993;611-621.
6. Stein C.A., LaRocca R.V., Thomas R., et al. Suramin an anticancer drug with a unique mechanism of action . J Clin Oncol. 4:1989;499-508.
7. Dawson N.A., Figg W.D., Cooper M.R., et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol. 15:1997;1470-1477.
8. Rosen P.J., Mendoza E.F., Landaw E.M., et al. Suramin in hormone-refractory metastatic prostate cancer a drug with limited efficacy . J Clin Oncol. 14:1996;1626-1636.
9. Klecker R., Collins J. Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography. J Liq Chromatogr. 8:1985;1680-1696.
10. Wittes RE: Manual of Oncologic Therapeutics, ed 1989-90. Philadelphia, JB Lippincott, 1989, pp 628-631.
11. Huggins C., Hodges C.V. Studies on prostatic cancer I. The effects of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
12. The Veterans Administration Co-operative Urological Research Group . Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 124:1967;1011-1017.
13. Eisenberger M.A. Chemotherapy for prostate carcinoma. NCI Monogr. 7:1988;151-163.
14. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 71:1993;1098-1109.
15. Coffey R., Leof E., Shipley G., et al. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B-cells. J Cell Phys. 132:1987;143-148.
16. Fruehauf J.P., Myers C.E., Sinha B.K. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer lines. J Natl Cancer Inst. 82:1990;1206-1209.
17. Kim J.H., Sherwood E.R., Sutkowski D.M., et al. Inhibition of prostatic tumor cell proliferation by suramin alterations in TGF-alpha-mediated autocrine growth regulation and cell cycle distribution . J Urol. 146:1991;171-176.
18. Bitton R.J., Figg W.D., Venzon D.J., et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol. 13:1995;2223-2229.
19. Holland E.J., Stein C.A., Palestine A.G. Suramin keratopathy. Am J Ophthalmol. 106:1988;216-220.
20. Collins J.M., Klecker R.W., Yarchoan R., et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 26:1986;22-26.
21. Reyno L.M., Egorin M.J., Eisenberger M.A., et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol. 13:1995;2187-2195.
22. Kobayashi K., Vokes E.E., Vogelzang N.J., et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 13:1995;2196-2207.
23. Stamey T.A., Kabalin L.N., Ferrari M., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV anti-androgen treated patients . J Urol. 141:1989;1088-1090.
24. Thalmann G.N., Sikes R.A., Chang S.M., et al. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst. 88:1996;794-801.
25. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
26. Eisenberger M.A., Sinibaldi V.J., Reyno L.M., et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol. 13:1995;2174-2186.